Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty

Christ Hospital Cardiovascular Research Center, Cincinnati, Ohio 45219, USA.

OBJECTIVES: The objectives of this double-blind, placebo-controlled, randomized dose-ranging study were 1) to examine the safety and tolerability of tirofiban (MK-383), a new nonpeptide platelet IIb/IIIa receptor antagonist, on a background of intravenous heparin and aspirin therapy; 2) to study the pharmacodynamics and pharmacokinetics of tirofiban; and 3) to evaluate the incidence of adverse cardiac outcomes (urgent repeat revascularization, myocardial infarction and death) with tirofiban versus placebo in a high risk subset of patients undergoing coronary angioplasty. BACKGROUND: Abrupt vessel closure complicates 4% to 8% of angioplasty procedures. Recent data have suggested that agents that antagonize the platelet glycoprotein IIb/IIIa receptor may reduce the incidence of adverse ischemic outcomes after coronary angioplasty. METHODS: Seventy-three patients received tirofiban in three sequential dose panels and 20 patients received placebo. Patients within each panel were randomized to receive either tirofiban or placebo in a 3:1 randomization design. Bolus doses of 5, 10 and 10 microg/kg and continuous infusion (16 to 24 h) doses of 0.05, 0.10 and 0.15 microg/kg per min were administered in panels I, II and III, respectively. Patients received concomitant heparin and aspirin for the angioplasty procedure. Data on patients receiving placebo (heparin and aspirin only) were pooled across panels for comparisons. The pharmacodynamic effect of tirofiban on ex vivo platelet aggregation to 5 micromol/liter adenosine diphosphate (ADP) and bleeding times were measured. Clinical outcomes were assessed in all patients, but the power to detect clinically meaningful differences (a one-third reduction in clinical events) between groups was limited (5%). RESULTS: Tirofiban was associated with a dose-dependent inhibition of ex vivo ADP-mediated platelet aggregation that was sustained during intravenous infusion and resolved rapidly after drug cessation. Adverse bleeding events, largely related to vascular access site hemorrhage, were slightly increased at the highest dose. Adverse clinical outcomes were infrequent in all patients and were not different among the small number of patients within each group. CONCLUSIONS: This study establishes a rational and generally well tolerated dosing regimen for administration of tirofiban as adjunctive therapy in high risk angioplasty patients. The impact of tirofiban on adverse clinical outcomes after angioplasty awaits definition by a larger clinical trial.

This article has been cited by other articles:

				M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi, A. W.J. van 't Hof, G. Campo, C. Hamm, J. ten Berg, L. Bolognese, F. Saia, G. B. Danzi, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur. Heart J., September 14, 2009; (2009) ehp376v1. [Abstract] [Full Text] [PDF]

				C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]

				C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]

				E. Karvouni, D. G. Katritsis, and J. P. A. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J. Am. Coll. Cardiol., January 1, 2003; 41(1): 26 - 32. [Abstract] [Full Text] [PDF]

				W. B. Batchelor, T. R. Tolleson, Y. Huang, R. L. Larsen, R. M. Mantell, P. Dillard, M. Davidian, D. Zhang, W. J. Cantor, M. H. Sketch Jr, et al. Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial Circulation, September 17, 2002; 106(12): 1470 - 1476. [Abstract] [Full Text] [PDF]

				A. L. Frelinger III, M. I. Furman, L. A. Krueger, M. R. Barnard, and A. D. Michelson Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation Circulation, September 18, 2001; 104(12): 1374 - 1379. [Abstract] [Full Text] [PDF]

				D. J. Fintel From bench to bedside: GP IIb-IIIa inhibitors Neurology, September 1, 2001; 57(90002): S12 - 19. [Abstract] [Full Text]

				E. J. Topol, D. J. Moliterno, H. C. Herrmann, E. R. Powers, C. L. Grines, D. J. Cohen, E. A. Cohen, M. Bertrand, F.-J. Neumann, G. W. Stone, et al. Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization N. Engl. J. Med., June 21, 2001; 344(25): 1888 - 1894. [Abstract] [Full Text] [PDF]

				J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 149 - 156. [Abstract] [Full Text] [PDF]

				C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119 (2009): 39S - 63S. [Full Text] [PDF]

				R Choussat, A Black, I Bossi, J Fajadet, and J Marco Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access Eur. Heart J., April 2, 2000; 21(8): 662 - 667. [Abstract] [PDF]

				A. M. Lincoff, R. M. Califf, and E. J. Topol Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1103 - 1115. [Abstract] [Full Text] [PDF]

				M. Verstraete Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa in Clinical Development Circulation, February 15, 2000; 101 (6): e76 - e80. [Abstract] [Full Text] [PDF]

				A. Brodison, R. Katira, R. S More, and A. Chauhan Current practice: Antiplatelet use in interventional cardiology Postgrad. Med. J., February 1, 2000; 76(892): 70 - 79. [Abstract] [Full Text]

				D. J Schneider, D. J Taatjes, and B. E Sobel Paradoxical inhibition of fibrinogen binding and potentiation of {alpha}-granule release by specific types of inhibitors of glycoprotein IIb-IIIa Cardiovasc Res, January 14, 2000; 45(2): 437 - 446. [Abstract] [Full Text] [PDF]

				J. B. Bussel, T. J. Kunicki, and A. D. Michelson Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease Hematology, January 1, 2000; 2000(1): 222 - 240. [Abstract] [Full Text] [PDF]

				R. M. Scarborough, N. S. Kleiman, and D. R. Phillips Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, July 27, 1999; 100(4): 437 - 444. [Abstract] [Full Text] [PDF]

				D. F. Kong, R. M. Califf, D. P. Miller, D. J. Moliterno, H. D. White, R. A. Harrington, J. E. Tcheng, A. M. Lincoff, V. Hasselblad, and E. J. Topol Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease Circulation, December 22, 1998; 98(25): 2829 - 2835. [Abstract] [Full Text] [PDF]

				R.F. Storey, R.G. Wilcox, and S. Heptinstall Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists Circulation, October 20, 1998; 98(16): 1616 - 1621. [Abstract] [Full Text] [PDF]

				T. Mann, G. Cubeddu, J. Bowen, J. E. Schneider, M. Arrowood, W. N. Newman, M. J. Zellinger, and G. C. Rose Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites J. Am. Coll. Cardiol., September 1, 1998; 32(3): 572 - 576. [Abstract] [Full Text] [PDF]

				C. M. Gibson, M. Goel, D. J. Cohen, R. N. Piana, L. I. Deckelbaum, K. E. Harris, S. B. King III, and for the RESTORE Investigators Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial J. Am. Coll. Cardiol., July 1, 1998; 32(1): 28 - 34. [Abstract] [Full Text] [PDF]

				R. A. Bednar, S. L. Gaul, T. G. Hamill, M. S. Egbertson, J. A. Shafer, G. D. Hartman, R. J. Gould, and B. Bednar Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1317 - 1326. [Abstract] [Full Text]

				J. H. Chesebro and J. J. Badimon Platelet Glycoprotein IIb/IIIa Receptor Blockade in Unstable Coronary Disease N. Engl. J. Med., May 21, 1998; 338(21): 1538 - 1541. [Full Text]

				T. R. Investigators Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty Circulation, September 2, 1997; 96(5): 1445 - 1453. [Abstract] [Full Text]

				D. R. Phillips, W. Teng, A. Arfsten, L. Nannizzi-Alaimo, M. M. White, C. Longhurst, S. J. Shattil, A. Randolph, J. A. Jakubowski, L. K. Jennings, et al. Effect of Ca2+ on GP IIb-IIIa Interactions With Integrilin : Enhanced GP IIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated With Citrate Circulation, September 2, 1997; 96(5): 1488 - 1494. [Abstract] [Full Text]

				U. Junghans, R. J. Seitz, H. J. Wittsack, A. Aulich, and M. Siebler Treatment of Acute Basilar Artery Thrombosis with a Combination of Systemic Alteplase and Tirofiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Inhibitor: Report of Four Cases Radiology, December 1, 2001; 221(3): 795 - 801. [Abstract] [Full Text] [PDF]